Healthcare-focused holding company Cardiff Lexington files for a $7 million Nasdaq uplisting
Cardiff Lexington, a holding company focused on acquiring business primarily in the healthcare sector, filed on Monday with the SEC to raise up to $7 million in an initial public offering. Cardiff Lexington originally filed for an IPO in July 2023, but later withdrew its filing in March 2025. The company is currently trading on the OTC under the symbol “CDIX”。
February 5, 2026 News
Healthcare-focused holding company Cardiff Lexington revises terms ahead of $6 million Nasdaq uplisting
Cardiff Lexington, which is holding company focused on acquiring business primarily in the healthcare sector, raised the proposed deal size for its upcoming IPO on Thursday.
January 20, 2026 News
Healthcare-focused holding company Cardiff Lexington sets terms for a $6 million Nasdaq uplisting
Cardiff Lexington, which is holding company focused on acquiring business primarily in the healthcare sector, announced terms for its IPO on Tuesday.
The Lexington, KY-based company plans to raise $6 million by offering 1.5 million shares at a proposed price of $4. At the proposed deal size, Cardiff Lexington would command a market cap of $65 million.
Company Overview
Cardiff Lexington is a healthcare-focused holding company that acquires and builds middle-market niche clinics, with an emphasis on orthopedics, spine care, and pain management. Its operating subsidiaries include Nova, which operates regional specialty and ancillary care facilities in Florida and Georgia serving traumatic injury patients, and Edge View, a real estate subsidiary holding undeveloped land in Idaho.
The Las Vegas, NV-based company was founded in 1986 and booked $12 million in revenue for the 12 months ended September 30, 2025. It plans to list on the Nasdaq under the symbol CDIX. R.F. Lafferty & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
Record Financial Growth in 2025
CDIX reported exceptional third-quarter 2025 results, showing dramatic expansion across all major financial metrics:
1、Q3 2025 Revenue: Up 125.6% to $3.1 million
2、Q3 2025 Gross Profit: Up 437.8% to $1.9 million
3、Q3 2025 Income from Continuing Operations: Up 209.9% to $643,000
Year-to-date performance further demonstrates consistent execution:
1、YTD Revenue: Up 70.2% to $8.8 million, compared to $5.1 million in the first nine months of 2024
2、YTD Gross Profit: Up 126.2% to $5.4 million
3、YTD Operating Income: Increased to $1.8 million, compared with a 2024 loss
Total Assets: Increased 15.4% to $27.6 million
These results reinforce the strength of the company’s scalable healthcare platform and its focused acquisition strategy.
A Healthcare Platform Built for Growth
All current CDIX revenues are generated through its subsidiary Nova Ortho and Spine, LLC, which operates a growing network of orthopedic, spine, and pain-management centers across Florida and Georgia. These centers deliver:
Comprehensive diagnostic and surgical services
Interventional pain management
Primary care evaluations
Specialty orthopedic and spinal consultations
CDIX’s model targets middle-market niche clinics that provide high-demand medical services—an area of the healthcare sector known for strong margins and consolidation opportunities.
First Procedures Completed at Doctor’s Memorial Hospital: Expanding Access to Rural Florida
On December 11th, CDIX announced a major operational milestone: Nova Ortho and Spine successfully performed its first procedures at Doctor’s Memorial Hospital in Perry, Florida.
This expansion represents more than growth—it signals a direct commitment to bringing high-quality orthopedic and pain-management care to severely underserved rural patient populations.
CEO Alex Cunningham commented
“Our presence at Doctor’s Memorial Hospital reinforces our commitment to providing best-in-class, accessible healthcare to the underserved and more rural areas around Florida. We quickly mobilized to bring our leading pain management and orthopedic and spinal surgical procedures to Taylor County, and we look forward to expanding into additional regions where we can further enhance healthcare standards and practices.”
This hospital integration is expected to support continued revenue growth while positioning CDIX as a regional leader in bridging healthcare gaps across the Southeast.
Strengthening Corporate Governance and Uplisting Readiness
A key part of CDIX’s growth strategy is its planned uplist to a senior exchange. Advancing that effort, the company recently entered into an advisory agreement with Greentree Financial Group, Inc., a firm specializing in corporate governance, financial reporting, and public-market compliance.
Greentree will guide CDIX on:
Audit processes
S-1 filing preparation
SEC and exchange responses
Governance enhancements
Coordination with attorneys, CPAs, and transfer agents
This engagement underscores the company’s commitment to financial discipline, transparency, and readiness to scale as a next-generation healthcare platform.
A Compelling Growth Story for Healthcare Investors
Cardiff Lexington has positioned itself at the intersection of rapidly growing healthcare demand, operational scalability, and underserved-market expansion. With a proven clinic-acquisition model and a successful track record of integrating and growing specialty medical centers, CDIX is strengthening its foundation for long-term value creation.
Investors watching the small-cap healthcare space may find CDIX’s trajectory notable:
Strong balance-sheet expansion
Triple-digit improvements in profitability
Strategic partnerships supporting an uplisting path
Continued expansion into high-need medical markets
As CDIX accelerates its footprint and advances its strategy, the company appears well-positioned for continued growth in 2026 and beyond.
About the Company
Our company is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in orthopedics, spine care, and pain management. Our partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance. We have a geographic specific acquisition strategy driven by targeted M&A execution across three synergistic complementary pillars: Core Cash Flow – Acquiring, optimizing, and managing physician practices to drive recurring revenue and operational efficiency; Asset Acquisition – Expanding our footprint through ownership of real estate assets such as ambulatory surgery centers and orthopedic clinics; Finance – Retaining and managing personal injury practice accounts receivable to capture long-term income rather than selling at deep discounts, strengthening sustainable profitability. We are focused on the acquisition of orthopedic and related modality practices with strong organic growth plans that are materially cash generative to maximize value and providing greater coverage for our patients, and diversification and risk mitigation for our stockholders. All current revenue is derived from Nova Ortho and Spine, LLC, or Nova, which was acquired on May 31, 2021.